Milken launches chronic disease research partnership with Armenian university gwhatchet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gwhatchet.com Daily Mail and Mail on Sunday newspapers.
A number of firms have modified their ratings and price targets on shares of Gossamer Bio (NASDAQ: GOSS) recently: 5/26/2022 – Gossamer Bio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $8.25 price target on the stock. According to Zacks, “Gossamer Bio Inc. […]
Gossamer Bio (NASDAQ:GOSS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The firm currently has a $8.25 price objective on the stock. Zacks Investment Research‘s target price indicates a potential upside of 11.79% […]
Gossamer Bio (NASDAQ:GOSS – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday, Zacks.com reports. According to Zacks, “Gossamer Bio Inc. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutics in the areas of immunology, inflammation […]
Gossamer Bio (NASDAQ:GOSS – Get Rating) had its price target cut by Barclays from $18.00 to $12.00 in a research report issued on Tuesday, The Fly reports. Barclays‘s price objective would indicate a potential upside of 32.16% from the company’s current price. GOSS has been the subject of several other reports. Piper Sandler cut their […]